Navigation Links
Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
Date:6/26/2012

SILVER SPRING, Md., June 26, 2012 /PRNewswire-USNewswire/ -- A new study on the effects of lorcaserin, a drug recently recommended for approval by an FDA advisory panel for the treatment of obesity, was just published in the scientific journal Obesity.  The journal is published by The Obesity Society (TOS), the leading scientific organization in North America dedicated to the study of obesity.  Authors include several TOS members including Patrick O'Neil, PhD, President, and Steven Smith, MD, Vice-President of TOS.

(Logo: http://photos.prnewswire.com/prnh/20120531/DC16753LOGO )

The study, titled BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus) evaluated 604 obese and overweight participants with type 2 diabetes in a double-blind placebo-controlled randomized trial over a one-year treatment period. Although all participants received systematic lifestyle change counseling, those on the medication lost 4.5 – 5.0% of their initial bodyweight compared to a loss of 1.5% by patients on the inactive placebo. According to lead author O'Neil, "That's a very meaningful difference in weight loss for this population. Importantly, the patients on active medication also showed much greater improvement on a key measure of blood glucose control."

Lorcaserin is a selective serotonin receptor agonist that works specifically on appetite signals in the brain. It has been developed by Arena Pharmaceuticals, which sponsored the trial. In previous clinical trials, lorcaserin decreased body weight in non-diabetic overweight and obese individuals. Although current American Diabetes Association treatment guidelines recommend that individuals with type 2 diabetes achieve modest weight loss (5–7%) to improve glycemic control, weight loss has historically been more difficult to achieve among patients with type 2 diabetes than among those without diabetes.

Over 85% of people with type 2 diabetes are overweight and obese people, and they often find weight loss more difficult than do non-diabetics. Weight losses of 5-10% can significantly improve glycemic control as well as other weight-related comorbid conditions. However, diet and exercise alone are often insufficient to achieve such weight losses in this population.  There are a variety of medications approved to treat health risks such as hypertension and hyperlipidemia, yet few have been approved to treat obesity, the greatest health threat of this century.

The Obesity Society is committed to encouraging research on the causes and treatment of obesity.  This new study on lorcaserin is one more example of the important research being conducted by TOS members to help inform both the medical community and the public.  "If approved by the FDA, lorcaserin will provide an additional tool to fill the gap between lifestyle intervention alone at one end and bariatric surgical intervention at the other end," said Dr. Robert Kushner, past president of The Obesity Society.  Dr. Kushner provided public comment to the advisory committee on behalf of The Obesity Society.

About The Obesity Society

The Obesity Society (www.obesity.org) is the leading scientific organization in North America dedicated to the study of obesity. The Obesity Society is committed to encouraging research on the causes and treatment of obesity and keeping the medical community and public informed of new advances. The Obesity Society's vision is to be the leader in understanding, preventing and treating obesity and in improving the lives of those affected. The Obesity Society's membership comprises approximately 2500 basic and clinical researchers, who have published extensively, and care providers in obesity treatment and prevention.

The Article Referenced in this News Release

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
Patrick M. O'Neil, Steven R. Smith, Neil J. Weissman, Meredith C. Fidler, Matilde Sanchez, Jinkun Zhang, Brian Raether, Christen M. Anderson and William R. Shanahan
Obesity (2012); 20 7, 1426–1436. doi:10.1038/oby.2012.66
http://www.nature.com/oby/journal/v20/n7/full/oby201266a.html


'/>"/>
SOURCE The Obesity Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MedVantx MedStart™ Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
2. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
3. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
4. NAMS Journal Menopause Reflects on the WHI 10 Years Later
5. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
6. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
7. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
8. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
9. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
10. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
11. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):